Member Info for dryland

@jim not great but we had a fourball and we won...was checking the SP as we were playing with a smile on my face..that was 3 games in 3 days day off tomorrow though :-) playing again saturday

i would like to add including mine ;-)

what do you all reckon the % is of drivel?

@James i didnt have any prior knowledge of it but the SP action was classic placing behaviour lots of buys and the ask continually dropping over a few days and dropping hard. Seen it many times before but obviously I couldn't be sure and could have been a coincidence but as it turns out...it wasn't. We have a leaky ship. I am expecting our major announcements which i expect pronto, if past behaviour is a guide here.

went golfing this morning and look what happened...coincidence? I think not....

you can if you are registered with Primary Bid

ok point taken and i agree i actually think this is a shrewd move for the company not so much for the investors in the short term. I was offered this from PB but i will take the chance add on the open market.

i will be whatever i want

bishop apology accepted

apology accepted numb nuts

apology accepted

there you go....apology accepted

all the signs were there Steven...the so called gurus on here wouldnt/couldnt accept it.

raising £45m that's impressive:
Use of Proceeds



Rapid Scale-up of Diagnostics Business, £10 million:

· Working capital for the COVID-19 testing opportunity

· Expansion of in-house diagnostics product development capabilities including facilities, capital equipment; scientific, commercial and senior leadership teams

· Acceleration of broader diagnostics product pipeline and commercial partnerships

Accelerated Expansion of Pipeline of Differentiated Cancer Therapies, £35 million:

· Rapidly growing the pre|CISION™ pre-clinical pipeline and delivering pre-clinical packages for several pro-drugs (pre|CISION™ velcade, paclitaxel and oxaliplatin).

· Expanding the Affimer® immunotherapy pipeline (PDL1-TGFß inhibitor and PDL1-cytokine bispecifics).

· IND/CTA filings for one or more Affimer immunotherapies (TMAC drug conjugate (PDL1-IDASH) or first bispecific candidate) and one or more pre|CISION pro-drugs.

· Obtain first-in-human data for the Affimer® platform.

· UK phase I clinical trial for first pre|CISION™ chemotherapy AVA6000 pro-doxorubicin covered by current balance sheet. Proceeds will fund IND filing AVA6000.

very graciious tim....

please send your apologies on a postcard

1pm manana Tim buenas noches

@timster ****** ;-)

deramping...your having a laugh I am heavily invested here...and i also have some powder dry for any further dips... i see by your posting history you are another newbie expert.

no need for the insults.
I agree on the face of it it doesn't look like they need cash but let's say they have been offered a lump of money similar to the last placing from insti's or HNWI in this current climate would it make sense to refuse it? Maybe...maybe not...i tell you something the SP action has had placing written all over it but maybe that is just a coincidence. The thing is i don't mind either way, and as i said earlier, i wouldnt necessarily see it as a bad move, depending on the price, and could possibly advance some of the projects.